EVerGel
undiscloseddrug program · medium
Publicly listed EVerZom therapeutic program; supplied material does not disclose the specific indication, but company-level objectives include exosome-based regenerative medicine for digestive tissue healing and liver and kidney regeneration.
Exosome/extracellular-vesicle regenerative medicine formulation; exact composition and route are not specified in the supplied material.
Listed in the company's therapeutic pipeline; no clinical phase or development milestone disclosed in the supplied material.
EVerZom exosome therapeutics platform
preclinicalplatform · high
Develop exosome-based therapeutics and co-development products for regenerative medicine, including digestive tissue healing and liver and kidney regeneration.
Integrated platform covering cell sourcing, exosome generation, exosome loading, and formulation.
Received non-dilutive EIC Accelerator funding of €2.5 million in 2026.
EViv
undiscloseddrug program · medium
Publicly listed EVerZom therapeutic program; supplied material does not disclose the specific indication, but company-level objectives include exosome-based regenerative medicine for digestive tissue healing and liver and kidney regeneration.
Exosome/extracellular-vesicle regenerative medicine product based on EVerZom's platform for cell sourcing, exosome generation, exosome loading, and formulation.
Listed in the company's therapeutic pipeline; no clinical phase or development milestone disclosed in the supplied material.
Hybrid extracellular vesicle drug delivery research
exploratoryresearch program · medium
Evaluate hybrid extracellular vesicles as drug-delivery vectors that combine EV properties with synthetic vector properties.
Review and comparative analysis of hybrid EV production methods including incubation, electrostatic interactions, PEG-mediated fusion, co-extrusion, freeze-thawing, and EV surface modification.
Publication reviewed methods and properties of hybrid EV/synthetic drug-delivery vectors.
The review identified multiple hybrid EV production approaches and noted limited availability of loading metrics enabling cross-article comparison.
MSC secretome bioproduction scale-up
exploratoryresearch program · high
Improve large-scale production of mesenchymal stromal cell-derived secretome and extracellular vesicles for regenerative medicine applications.
Bead-to-bead transfer in stirred-tank bioreactors with successive microcarrier additions to scale MSC secretome production.
2025 publication reported scalable MSC secretome production using bead-to-bead transfer.
The study reported 428 million MSCs in 16 days, 5.3 cumulative population doublings, 2.4-fold higher particle/cell yield, 88-fold higher total particle production, and 113-fold higher particle productivity versus static flasks; EVs displayed CD9, CD81, CD63, and MSC markers.
MSC secretome immunomodulation mechanism program
exploratoryresearch program · high
Characterize which MSC secretome fractions mediate innate immune pathway modulation and T-cell proliferation effects to inform cell-free MSC-based therapies.
PBMC, THP-1 dual reporter, tangential-flow filtration, ultracentrifugation, and flow-cytometry assays comparing soluble and extracellular-vesicle-containing fractions.
2025 publication described size-dependent immunomodulatory mechanisms of MSC secretome fractions.
Clarified secretome and soluble ultracentrifugation fractions inhibited NF-kappaB and IRF activation in a dose-dependent manner, partly through prostaglandin E2; T-cell proliferation inhibition was associated with concentrated secretome components larger than 100 kDa.
Oxygen-conditioned MSC secretome optimization
exploratoryresearch program · high
Optimize MSC culture oxygen conditions to improve regenerative bioactivity of secretome and extracellular vesicles.
Human Wharton's Jelly MSCs cultured for 7 days at 2%, 10%, and 19% oxygen in stirred Ambr 250 bioreactors, followed by size-exclusion chromatography and functional assays.
2026 publication evaluated oxygen conditioning effects on MSC secretome production and function.
2% oxygen increased cell proliferation and cell density but reduced particle and protein yield per cell; conditioned media and isolated EVs from 2% oxygen cultures showed superior promotion of osteoblast and HUVEC proliferation, migration, and angiogenic potential.
